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Abstract
Purpose Missing data are a major problem in the analysis
of data from randomised trials affecting power and
potentially producing biased treatment effects. Specifically
focussing on quality of life outcomes, we aimed to report
the amount of missing data, whether imputation was used
and what methods and was the missing mechanism dis-
cussed from four leading medical journals and compare the
picture to our previous review nearly a decade ago.
Methods A random selection (50 %) of all RCTS pub-
lished during 2013–2014 in BMJ, JAMA, Lancet and
NEJM was obtained. RCTs reported in research letters,
cluster RCTs, non-randomised designs, review articles and
meta-analysis were excluded.
Results We included 87 RCTs in the review of which
35 % the amount of missing primary QoL data was
unclear, 31 (36 %) used imputation. Only 23 % discussed
the missing data mechanism. Nearly half used complete
case analysis. Reporting was more unclear for secondary
QoL outcomes. Compared to the previous review, multiple
imputation was used more prominently but mainly in
sensitivity analysis.
Conclusions Inadequate reporting and handling of missing
QoL data in RCTs are still an issue. There is a large gap
between statistical methods research relating to missing
data and the use of the methods in applications. A sensi-
tivity analysis should be undertaken to explore the sensi-
tivity of the main results to different missing data
assumptions. Medical journals can help to improve the
situation by requiring higher standards of reporting and
analytical methods to deal with missing data, and by
issuing guidance to authors on expected standard.
Keywords Missing data  Quality of life  Randomised
controlled trial  Imputation
Introduction
The randomised controlled trial (RCT) is often regarded
the gold standard study design for evaluating healthcare
interventions but can be prone to missing outcome data. At
best missing data reduce the sample size and power of an
RCT and at worst could bias results. Patient-reported
quality of life (QoL) outcomes are essential to inform
decisions about best available treatments. Missing data are
problematic for any outcome, but with QoL outcomes
missing data are often informative. Ignoring missing data
may bias estimates of treatment effects. The literature is
extensive on the consequences of ignoring missing data
and methods to deal with it [1–4]. Guidelines do exist, but
the question remains as to whether these guidelines are
being followed [5]. Understanding the mechanism of the
missing data is not a new concept. Little and Rubin defined
three missing data mechanisms: missing completely at
random (MCAR), missing at random (MAR) and missing
not at random (MNAR) [6]. It is difficult to prove data are
MNAR because by definition the data are missing, but it is
possible to differentiate between MCAR and MAR [7].
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Methods of analysis depend on the missing data assump-
tion; however, published reports of RCTs rarely justify the
method choice [1].
The simplest method for handling missing data is to
ignore it and use complete case analysis (CCA). In CCA,
all participants with missing data are excluded. CCA is,
however, suitable only if data are MCAR and the missing
data proportion is small [4]. CCA produces biased esti-
mates if data are MAR or MNAR. The use of sensitivity
analysis to test the impact of different missing data
assumptions is useful [5]. This may include imputation
which can be something as simple as last value carried
forward (LVCF), mean imputation or alternatively the
more complex multiple imputation. The latter allows for
more uncertainty by creating multiple imputed values and
then using Rubin’s rules to combine the results [6–8].
In situations where data are collected repeatedly, the use of
a repeated measures approach with the MAR assumption
may be sensible. For MNAR, more sophisticated methods
such as pattern mixture models may be useful, but these are
less accessible to the average researcher [9, 10].
In 2008, we published a review of RCTs appearing in
four medical journals during 2005–2006 and assessed the
use of imputation to overcome missing QoL outcome data
[1]. The aim here is to undertake a similar review of arti-
cles published in the same four journals during 2013–2014
to ascertain whether the picture has changed in light of that
review and other similar recent literature. Specifically, we
aim to report the amount of missing data, whether impu-
tation was used and what methods and was the missing
mechanism discussed. We will compare the findings to
those of our previous review.
Methods
The search
We searched MEDLINE and Embase for RCTs published
during 2013 and 2014 in four leading medical journals: the
British Medical Journal (BMJ), the Journal of American
Medical Association (JAMA), the New England Journal of
Medicine (NEJM) and the Lancet. These four journals were
chosen as they are often the first choice for publication of
RCT results. Inclusion criteria were any RCT published in
one of the four target journals (BMJ, JAMA, NEJM,
Lancet) during 2013 or 2014. RCTs reported in research
letters, cluster RCTs (as statistical issues differ as ran-
domisation does not occur at individual level), non-ran-
domised designs, review articles and meta-analyses were
excluded. Figure 1 details the selection of studies to be
included. The search identified 851 trials, and after removal
of duplicates and ineligible studies on title and abstract, we
had 573 for potential inclusion. A random sample of 50 %
was taken forwards to full text review (N = 290). No
quality assurance was undertaken as we were not interested
in the results of the studies. Abstract review was under-
taken by one researcher (AO) after an initial double
screening of 25 articles by a second reviewer (SF or SS). In
all 25 cases, agreement on inclusion was agreed, so
thereafter, only one reviewer undertook the abstract
screening, with any uncertainties about inclusion discussed
with a second reviewer (SF).
Data extraction and analysis methods
We extracted basic information about each RCT including:
amount of missing data, type of QoL outcome, was
imputation used (if so what method), number of interven-
tion arms, number randomised, whether the mechanism of
missing data was discussed, analysis method used and if
sensitivity analysis was undertaken. Extraction of infor-
mation was restricted to the main QoL outcome (whether
that be a primary or secondary outcome within the RCT).
One researcher (AO) carried out data extraction, after an
initial pilot of double abstraction (SF or SS) of 50 articles
showed consistency between reviewers. Any queries on
singly abstracted articles were resolved with a second
reviewer (SF).Information collected was then entered into
an IBM SPSS Statistics 22 database. Frequencies and
percentages for characteristics of included RCTs were
shown. Continuity corrected Chi-squared tests were used to
compare outcomes between our previous review [1] and
this current review. On completion of analysis, SF double-
checked the key information from each included article to
ensure accuracy. A few corrections were made, and anal-
ysis rerun to produce the results contained here.
Results
Search results
Figure 1 shows the searching process yielding 256 RCTs for
the review. The majority of RCTs (n = 195, 76 %) were
two-arm studies, with a further 36 (14 %) three arms and the
remaining 21 (8 %) four or more arms. Most of the studies
were of parallel design (94 %) with four studies (2 %) using
a crossover design and 11 (4 %) a factorial design. Within
the 256 RCTs, 91 (36 %) said they included a QoL outcome;
however, in four RCTs the analysis of the QoL was not
reported and these were excluded. We included 87 RCTs in
which at least oneQoL outcomewas reported in 34 (39 %) as
primary outcome, 57 (61 %) as secondary outcome).
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Description of missing data
Table 1 describes the amount of missing data. Four RCTs
reported no missing data, and it was unclear for 30 (35 %).
In the 52 RCTs not using imputation, 17 (33 %) had an
unclear amount of missing data and 18 had less than 10 %
missing. In the 31 RCTs that used imputation, for ten
(29 %) the amount of missing data was unclear and 13
(39 %) had less than 10 % missing, 7 (21 %) had between
10 and 20 % missing with only one having more than 20 %
missing. A comparison between the amount missing
between primary QoL and secondary QoL found that it was
unclear for 12 % of primary QoL but 49 % of secondary
QoL (data not shown).
The missing data mechanism was discussed in 19/83
(23 %) of eligible RCTs, as four had no missing data.
However, an indication of which mechanism was only
provided for 11 (eight MAR, two MCAR, one MNAR).
The remaining 64/83 (77 %) RCTs had no discussion of the
missing data mechanism at all.
Quality of life measures used
A variety of QoL measures were used; the main QoL
outcome in 34 (39 %) RCTs was a generic measure such as
EQ-5D or SF-12/SF-36. The remaining 61 % were disease
specific measures covering a wide range of disease areas.
Examples included: QLQ-C30, PDQ39, Seattle Angina




































RCTs included (n = 256)
NEJM (n = 101, 39%)
JAMA (n = 72, 28%)
Lancet (n = 63, 25%)
BMJ (n = 20, 8%)
Records excluded: ineligible 
based on title and/or abstract 
(n = 71)
Full-text articles excluded 
after the random selection of 
50% (n = 283)
Studies excluded
(n = 34)
27 were cluster RCTs
2 duplicates
5 non RCT
Fig. 1 PRISMA flow diagram
for study inclusion
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Questionnaire, Ankylosing Spondylitis QoL, DEMOQOL
(QoL for people with dementia), Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC),
Function assessment of Chronic Illness therapy-fatigue
(FACIT-F), Visual Function questionnaire (VFQ-25) and
Brief Pain Inventory.
Imputation methods
Table 2 describes basic characteristics of the 87 included
RCTs that contained aQOLoutcome. TheQoL outcomewas
continuous in 63 (72 %) RCTs and analysed at a single
endpoint in 57 RCTs (66 %). In total, 18 (21 %) RCTs used
imputation within their primary analysis, and a further 13
(15 %) RCTs used it within a sensitivity analysis resulting in
31/87 (36 %) includedRCTs using some form of imputation.
For the 18 RCTs employing imputation within their
primary analysis, four used last value carried forwards
(LVCF); five used worst case scenario; one mean value
imputation; seven used multiple imputation (two chained
equations, one Markov chain Monte Carlo (MCMC) and
unclear for four). Of the 13 RCTs where imputation was
used as a sensitivity analysis, twelve used multiple impu-
tation (with only one indicating which method, predictive
mean match) and one used worst case scenario.
Analysis methods
The primary analysis strategy for the QoL outcome was a
complete case analysis for 42/87 RCTs (48 %) and 33
(38 %) a repeated measures approach, the remainder using
imputation (Table 2). Twelve of the 33 RCTs which used a
repeated measures approach did so with imputation
undertaken as well (six within primary analysis and six
within sensitivity). The main complete case analysis was
linear regression/analysis of covariance as the majority of
QoL outcomes were continuous.
Comparison of results to the previous review
Table 3 shows a main comparison of the findings from our
previous review [1] and those we have identified in the
current review. We can see there has been an increase in











None 4 0 0 4 (5 %)
\5 % 9 6 0 15 (17 %)
5–10 % 9 7 0 16 (18 %)
11–20 % 6 7 0 13 (15 %)
[20 % 7 1 1 9 (10 %)
Unclear 17 10 3 30 (35 %)
Table 2 Description of the 87 RCTs with a QoL outcome included in the review
Primary QoL (N = 34) Secondary QoL (N = 53) Total (N = 87)
Journal BMJ 6 (18 %) 6 (11 %) 12 (14 %)
NEJM 11 (32 %) 18 (34 %) 29 (33 %)
JAMA 4 (12 %) 14 (26 %) 18 (21 %)
Lancet 13 (38 %) 15 (28 %) 28 (32 %)
Number of intervention arms 2 27 (79 %) 49 (92 %) 76 (87 %)
3 5 (15 %) 2 (4 %) 7 (8 %)
4? 2 (6 %) 2 (4 %) 4 (5 %)
QoL outcome Binary 7 (21 %) 2 (4 %) 9 (10 %)
Continuous 20 (59 %) 43 (81 %) 63 (72 %)
Categorical 7 (21 %) 6 (11 %) 13 (15 %)
Count 0 (0 %) 1 (2 %) 1 (1 %)
Other 0 (0 %) 1 (2 %) 1 (1 %)
Endpoint Single 18 (53 %) 39 (74 %) 57 (66 %)
Repeated 16 (47 %) 14 (26 %) 30 (34 %)
Analysis Complete case 21 (62 %) 35 (66 %) 56 (64 %)
Imputation 2 (6 %) 10 (19 %) 12 (14 %)
Repeated measures 11 (32 %) 8 (15 %) 18 (21 %)
Imputation used Yes in primary analysis 7 (21 %) 11 (21 %) 18 (21 %)
Yes as sensitivity 8 (24 %) 5 (9 %) 13 (15 %)
No 19 (56 %) 33 (62 %) 52 (60 %)
Unclear 0 (0 %) 4 (8 %) 4 (5 %)
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the proportion of RCTs reporting at least one QoL outcome
(21.4–34.0 %, p = 0.001). This increase in the use of QoL
outcomes is not surprising given the recent emphasis on
patient-reported outcomes within RCTs.
Despite a slight increase in the proportion of RCTs using
imputation, the difference was not significant (p = 0.696).
Imputation methods used previously focussed around
simple imputation, whereas now we have seen a shift and a
higher number have used multiple imputation (20/31 using
MI here compared to only 1/19 in the previous review,
p\ 0.001). The amount of missing data was broadly
similar.
Discussion
We have found that QoL outcomes are increasingly being
used as outcomes within RCTs, and missing data are still a
major problem. In particular, compared to 2005 review,
there is less clarity on the description of missing data for
secondary outcomes. Researchers favoured simple but
potentially biased methods such as last value carried for-
wards or worse value imputation in their main analysis.
Multiple imputation was used more frequently than in our
previous review but mainly for sensitivity analyses. Dis-
cussion of the missing data mechanism was limited, so it is
unclear whether the imputation methods used were
appropriate as insufficient information is provided by
authors. Although researchers appear more aware, they
should account for missing data their primary analyses
were still often based on complete case analysis.
Our findings are specific to QoL outcomes; however,
what we have found is mirrored in more general reviews
such as Wood et al. [2] and Bell et al. [3]. In both of these,
they found complete case was the most common analysis
strategy, and simple imputation used more often than
multiple imputation despite recommendations against it.
Like us, they also found that reporting of the assumptions
around the missing data mechanism was limited.
In our previous review, we recommended clearer
reporting of missing data, the impact of missing data dis-
cussed and sensitivity analyses reported. It is clear from our
current review and others that this is still not being
undertaken appropriately in the majority of studies [3, 11].
In situations of longitudinal data, many studies did not
exploit the repeated nature of the data in the analysis, and
participants were excluded within a complete case because
they did not have data for the final endpoint. In a mixed
model, for example, these participants would have been
included if they had provided at least one QoL assessment
at some other time. Where multiple imputation was used, it
was not always clear what the imputation model contained.
This should be reported, and at the very least it should
contain any variables used in the randomisation process
and those used in the analysis model [12] It would be
advantageous to use other auxiliary variables which may
improve the imputation, e.g., using a previous QoL score to
impute one that is missing [9, 12].
The four journals covered in this review are four of the
top five medical journals with respect to impact factors.
Using only these four could be considered a potential
limitation. As these journals are considered the pinnacle of
RCT publication, one might argue they should have the
best reporting standards; however, this is potentially not the
case. While we have limited our research to these four
journals, the findings will be directly applicable to any
journal which contains articles reporting the results of
RCTs. The four journals provide very few guidelines on
how to report missing data. The Lancet and BMJ direct
authors to adhere to the CONSORT guidelines [13], but
JAMA and NEJM make no such recommendations. The
CONSORT checklist for reporting RCTs indicates infor-
mation should be provided on loss to follow-up and the
reason for exclusion, along with numbers randomised and
analysed. Reporting of missing data is not mentioned
directly in the statement. We compared the type of analy-
sis, whether or not missing data mechanism was discussed,
imputation use and missing data proportion between those
articles published in BMJ/Lancet versus NEJM/JAMA to
ascertain whether this recommendation of using the
CONSORT made a difference (supplementary Table 1).
No differences were found, indicating that the missing data
reporting was no better in those journals who directed
authors towards the CONSORT statement. While we can-
not conclude a causal effect, this suggests the CONSORT
is not adequate in providing guidelines to authors on how
to report missing data for their RCTs.
However, more recently, Calvert et al. [14] have
reported an extension to CONSORT for patient-reported
outcomes, namely CONSORT PRO. In the CONOSRT
Table 3 Comparison of 2005–2006 and 2013–2014 RCTs
2005–2006 2013–2014
RCTs reviewed 285 256
Include QoL outcome 61 (21.4 %) 87 (34.0 %)
Imputation 19/61 (31.1 %) 31/87 (35.6 %)
Use of MI 1 20
Missing data discussed
Proportion of missing data N = 61 N = 87
None 9.8 4.6
\10 % 34.4 35.6
11–20 % 18.0 14.9
[20 % 18.0 10.3
Unclear 19.7 34.5
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PRO, statement P12a says ‘Statistical approaches for
dealing with missing data are explicitly stated’. This is an
important addition as it directly asks authors whether they
have stated how they have dealt with missing data of
patient-reported outcomes. This guidance was only pub-
lished in 2013, so perhaps too recent to be reflected in the
articles we have included in our review.
If authors are directed to the CONSORT checklist (and
not CONSORT PRO), reporting of missing data is not
explicitly detailed. Therefore, it is perhaps not surprising
that authors still tend to favour complete case analysis. The
reasons for this are unknown; however, from our own
experience this may be due to word count issues or indeed
some of the authors of this paper have tried to include an
MI model into a manuscript, but the journal has insisted it
is put in the supplement. The European Medicine Agency
in 2010 recommended that studies provide ‘a detailed
description of pre-planned methods used for handing
missing data, and amendment of that plan and justification
for those amendments should be included in the study
report’ [15]. This raises the question to educate not just
authors in how best to report missing data but also the
journal editors who are deciding what articles are
published.
QoL outcomes from RCTs increasingly inform cost-ef-
fectiveness analyses used by policy makers to decide on the
allocation of resources. For example in the UK, the
National Institute for Health and Care Excellence (NICE)
relies on trial data (both clinical and cost-effectiveness) to
make decisions about what treatments/interventions to use
in the NHS. Therefore, it is imperative that findings from
RCTs are robust that includes assessing the impact of and
dealing with any missing data. Ignoring missing data may
result in misleading findings through biased and imprecise
estimates of treatment effects.
Conclusions
Inadequate reporting and handling of missing QoL data in
RCTs are still an issue. As Bell et al. concluded that there
is an apparent large gap between statistical methods
research relating to missing data and the use of the methods
in applications, i.e., RCTs [3]. Medical journals could help
to improve the situation by requiring higher standards of
reporting and analytical methods to deal with missing data,
and by issuing guidance to authors on expected standard.
CONSORT is the gold standard of reporting RCTs, and
journals direct authors towards CONSORT, but perhaps the
checklist for RCTs needs to be more explicit about what
information should be reported in regard to missing data.
Journals should now direct authors to CONSORT PRO so
if they have included a patient-reported outcome it is
reported adequately. In addition, the missing data statement
for QoL outcomes may encourage more information to be
provided by authors on the other outcomes in their trials.
Researchers themselves need to take responsibility for
reporting detail in their own manuscripts and if reviewing
manuscripts for journals or colleagues, ensure that they
raise this issue where detail is lacking.
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